StreetInsider.com News Articles

Form 8-K Aclaris Therapeutics, For: Mar 10

Wed, 11 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260311/26146544.html

Form 8-K Aclaris Therapeutics, For: Mar 10

Wed, 11 Mar 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260311/26146544.html

Form 8-K Aclaris Therapeutics, For: Mar 09

Tue, 10 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260310/26134804.html

Form 8-K Aclaris Therapeutics, For: Mar 09

Tue, 10 Mar 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260310/26134804.html

Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin

Tue, 03 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260303/26101554.html

Form 4 Aclaris Therapeutics, For: Mar 01 Filed by: Balthaser Kevin

Tue, 03 Mar 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260303/26101554.html

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Tue, 03 Mar 2026 07:00:00 -0400

WAYNE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday March 10, 2026, at 1:40 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Leerink Partners 2026 Global Healthcare Conference in Miami, FL.

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Tue, 03 Mar 2026 07:00:00 -0400

A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The

Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel

Fri, 27 Feb 2026 09:05:34 -0400

Stifel analyst Alex Thompson raised the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $3.00 (from $2.00) while maintaining a Hold rating.

The analyst comments "We remain Hold rated on ACRS following its 4Q25 update. While the company's in-licensed biologics portfolio including an IL-4RxTSLP bipsec (ATI-052) and TSLP mAb (bosakitug) sit within strategically-important and growing areas within the I&I space, we lack conviction in a differentiation thesis amid growing competition. Preliminary SAD/MAD data for ATI-052 underscores our concerns around receptor pairings for bispecfics with a relatively short 26- day half-life--PoC AD/Asthma data expected 2H26. Additionally, we are uncertain whether bosakitug's increased

Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel

Fri, 27 Feb 2026 09:05:34 -0400

Stifel analyst Alex Thompson raised the price target on Aclaris Therapeutis (NASDAQ: ACRS) to $3.00 (from $2.00) while maintaining a Hold rating.

Form 10-K Aclaris Therapeutics, For: Dec 31

Thu, 26 Feb 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260226/26071789.html

Form 10-K Aclaris Therapeutics, For: Dec 31

Thu, 26 Feb 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260226/26071789.html

Aclaris Therapeutics (ACRS) Misses Q4 EPS by 1c

Thu, 26 Feb 2026 07:46:59 -0400

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $1.3 million versus the consensus estimate of $1.94 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

Form 8-K Aclaris Therapeutics, For: Feb 26

Thu, 26 Feb 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260226/26064347.html

Form 8-K Aclaris Therapeutics, For: Feb 26

Thu, 26 Feb 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260226/26064347.html

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Thu, 26 Feb 2026 06:58:00 -0400

- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 -

- Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Thu, 26 Feb 2026 06:58:00 -0400

- Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis

Aclaris Therapeutics begins phase 1b trial of ATI-052 in asthma patients

Tue, 24 Feb 2026 07:00:26 -0400

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has initiated a placebo-controlled Phase 1b proof-of-concept trial of ATI-052, its investigational bispecific anti-TSLP/IL-4Rα antibody, in patients with asthma, according to a company statement.

The randomized, double-blind trial will evaluate the safety, tolerability, and efficacy of ATI-052 compared to placebo in approximately 16 patients with asthma on GINA steps 2-4 treatment prior to screening. The study follows the recent initiation of a similar Phase 1b trial of ATI-052 in atopic dermatitis.

Endpoints include safety and tolerability parameters, pharmacokinetic parameters, respiratory pharmacodynamic biomarker assessments including fractional exhaled nitric oxide, blood biomarker assessments including blood eosinophil count and endogenous

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Tue, 24 Feb 2026 07:00:00 -0400

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in asthma. This announcement follows the recent initiation of the Company’s Phase 1b POC trial of ATI-052 in atopic dermatitis (AD). Planning is ongoing for a Phase 2b program encompassing asthma and atopic dermatitis as potential first indications. The Company expects to initiate this program in the second half

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

Tue, 24 Feb 2026 07:00:00 -0400

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.

Mon, 09 Feb 2026 13:42:00 -0400

si-local-file:///var/storage/secattach/20260209/25967243.html

Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: BML Investment Partners, L.P.

Mon, 09 Feb 2026 13:42:00 -0400

si-local-file:///var/storage/secattach/20260209/25967243.html

Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Walker Neal

Fri, 06 Feb 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260206/25962942.html

Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Walker Neal

Fri, 06 Feb 2026 18:10:00 -0400

si-local-file:///var/storage/secattach/20260206/25962942.html

Form 4 Aclaris Therapeutics, For: Feb 02 Filed by: Davis Hugh M.

Fri, 06 Feb 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260206/25962928.html